CML therapy has shifted towards long-term disease management and maintaining a deep molecular response according to the BCR-ABL polymerase chain reaction (PCR) test on peripheral blood. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.